http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104311672-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70 |
| filingDate | 2014-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104311672-B |
| titleOfInvention | A kind of inhibitor polypeptide with tumour cell targeting |
| abstract | The invention belongs to biotech medicine product technical field, and in particular to a kind of inhibitor polypeptide with tumour cell targeting.The present invention devises whole amino acid sequences of the tumor inhibitor TA 2.TA 2 containing thymic peptide a1 with tumour cell targeting, and contains tumour cell targeted polypeptide fragment arginine glycine arginine aspartate sequence in its c-terminus.TA of the invention 2 is the gene engineering product in expression in escherichia coli, and its purge process includes the induced expression of albumen, affinity chromatography, gel chromatography.The product test in vivo and in vitro in embody significantly improve original thymic peptide a1 antitumor cell growth effect, its have remarkable effect tumour include lung cancer, melanoma, breast cancer is in interior solid tumor. |
| priorityDate | 2014-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.